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Abstract
Objective—This study tests the hypothesis that injury to the somatosensory cortex is associated
with periorbital allodynia and increases in nociceptive neuropeptides in the brainstem in a mouse
model of controlled cortical impact (CCI) injury.
Methods—Male C57BL/6 mice received either CCI or craniotomy-only followed by weekly
periorbital von Frey (mechanical) sensory testing for up to 28 days post-injury. Mice receiving an
incision only and naïve mice were included as control groups. Changes in calcitonin gene-related
peptide (CGRP) and substance P (SP) within the brainstem were determined using enzyme-linked
immunosorbent assay and immunohistochemistry, respectively. Activation of ionized calcium-
binding adaptor molecule-1–labeled macrophages/microglia and glial fibrillary acidic protein
(GFAP)-positive astrocytes were evaluated using immunohistochemistry because of their potential
involvement in nociceptor sensitization.
Results—Incision-only control mice showed no changes from baseline periorbital von Frey
mechanical thresholds. CCI significantly reduced mean periorbital von Frey thresholds (periorbital
allodynia) compared with baseline and craniotomy-only at each endpoint, analysis of variance P
< .0001. Craniotomy significantly reduced periorbital threshold at 14 days but not 7, 21, or 28
days compared with baseline threshold, P < .01. CCI significantly increased SP immunoreactivity
in the brainstem at 7 and 14 days but not 28 days compared with craniotomy-only and controls, P
< .001. CGRP levels in brainstem tissues were significantly increased in CCI groups compared
with controls (incision-only and naïve mice) or craniotomy-only mice at each endpoint examined,
P < .0001. There was a significant correlation between CGRP and periorbital allodynia (P < .0001,
r = −0.65) but not for SP (r = 0.20). CCI significantly increased the number of macrophage/
microglia in the injured cortex at each endpoint up to 28 days, although cell numbers declined
over weeks post-injury, P < .001. GFAP+ immunoreactivity was significantly increased at 7 but
not 14 or 28 days after CCI, P < .001. Craniotomy resulted in transient periorbital allodynia
accompanied by transient increases in SP, CGRP, and GFAP immunoreactivity compared with
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control mice. There was no increase in the number of macrophage/microglia cells compared with
controls after craniotomy.
Conclusion—Injury to the somatosensory cortex results in persistent periorbital allodynia and
increases in brainstem nociceptive neuropeptides. Findings suggest that persistent allodynia and
increased neuropeptides are maintained by mechanisms other than activation of macrophage/
microglia or astrocyte in the injured somatosensory cortex.
Keywords
post-traumatic headache; traumatic brain injury; calcitonin gene-related peptide; trigeminal;
allodynia; central sensitization
Long-term disability from traumatic brain injury (TBI) is prevalent occurring in
approximately 3.17 million persons on an annual basis.1 Among the long-term consequences
of TBI, post-traumatic headache (PTH) disorder represents the most common chronic pain
syndrome within this patient population.2–7 PTH disorders are highly prevalent across all
grades of TBI severity.8 Mild and moderate TBI is more prevalent compared to severe cases
of TBI; however, there is a current controversy surrounding epidemiologic reports that cite a
higher incidence of PTH for mild TBI compared with moderate and severe cases. A recent
prospective 12-month study of TBI patients provides compelling evidence that the
prevalence of PTH is unrelated to injury severity.9
Important aspects of PTH to consider relate to the time-course of this disorder. In many
patients, it resolves in 3 months; in others, it persists for much longer. Currently, PTH, as
classified by the International Classification of Headache Disorders, is defined as headache
secondary to head trauma that develops within 7 days after injury or regaining
consciousness. TBI is a risk factor for acute episodic headache (headache occurring less than
15 days/month) persisting less than 3 months transitioning into chronic headache (≥15 days/
month).10,11 Clinical evidence suggest that the persistence of PTH beyond the expected
tissue-healing time-course would argue for its chronicity, as well as mechanisms of central
sensitization.12–14 A recent prospective study found the onset of PTH occurred between 7
and 30 days after injury or later in nearly half of patients.15 A study by Ofek and Defrin
found that patients with TBI had a mean onset of chronic pain, including head pain, just over
6 months after injury.14 Headache was reported at 3, 6, and 12 months in 41% of patients
with TBI in a study by Hoffman and colleagues.9 Studies using quantitative sensory testing
(eg, von Frey mechanical stimuli for allodynia [cutaneous sensitivity to mechanical stimuli
that are innocuous under normal conditions]) show that 40% of patients with TBI experience
chronic head and face pain after head injury.14,16 Significant reductions in pressure-pain
thresholds were found at least 1 year after mild-to-moderate TBI.16 To date, investigations
into the proposed mechanisms and treatments for PTH have been impeded by a lack of
preclinical models. Therefore, a research initiative implemented by our laboratory is to study
mechanisms of PTH and its chronification using a well-known animal model of TBI,
controlled cortical impact (CCI) injury.
Headache pain, whether acute or chronic, involves abnormal activation of the
trigeminovascular system. Using a model of diffuse TBI, Hall and Lifshitz have
Elliott et al. Page 2













characterized hypersensitivity of the whiskers to be associated with neuroplasticity in the
cortical barrel circuit and thalamus.17 Peripheral axons of the trigeminal ganglion innervate
the peri-orbital skin, facial whiskers, anterior scalp, meninges, and cerebral vasculature.
Periorbital and facial allodynia have been well-documented in rodent migraine models
following infusion of an inflammatory soup over the meninges.18–20 Afferent fibers of the
trigeminal ganglia relay nociceptive information to the trigeminal nuclei in which the
neuropeptides, calcitonin gene-related peptide (CGRP) and substance P (SP), play important
roles. CGRP and SP are also important in normal physiologic and pathologic function
including cerebrovascular regulation and the development of neurogenic inflammation.21–26
CGRP has been particularly well-studied for its role in primary headache disorders such as
migraine.27,28 To date, preclinical studies examining allodynia and the potential role of
CGRP and SP in PTH are nonexistent. This study aimed to characterize periorbital sensory
changes to mechanical stimuli (allodynia) and neuroplasticity in the brainstem in a mouse
model of TBI, as this has not yet been reported in any model of TBI.
The present study tests the hypothesis that focal injury to the somatosensory cortex will be
associated with increased neuropeptides within the brainstem trigeminal nucleus caudalis
and periorbital allodynia in a mouse model of CCI injury. The time-course for macrophage/
microglial and astrocyte responses in the somatosensory cortex after CCI were examined
because these cell populations are a potential cellular source of mediators (eg, cytokines,
nitric oxide [NO], excitatory amino acids) of nociceptor sensitization known to contribute to
behavioral morbidity. The pattern of periorbital allodynia over 4 weeks in mice with CCI
and those undergoing a craniotomy only was characterized, while changes in the nociceptive
neuropeptides, CGRP, and SP within the brainstem were determined. The temporal
relationships between periorbital sensory changes (allodynia), central nociceptive
neuropeptides, and gliosis (macrophage/microglia and astrocyte activation) were examined.
EXPERIMENTAL PROCEDURES
Experimental Design, Animal Care, and Anesthesia
Prior to initiating any research, the Thomas Jefferson University Institutional Animal Care
and Use Committee reviewed and approved the research protocol and approved the use of
male C57BL/6 mice from Charles River as experimental animals. Animal care and use was
monitored by the University Animal Care and Use Committee to assure compliance with the
provisions of Federal Regulations and the National Institutes of Health (NIH) “Guide for the
Care and Use of Laboratory Animals.” All animals were housed in the Thomas Jefferson
University Laboratory Animal Services Facility that is accredited by the American
Association for the Accreditation of Laboratory Animal Care and complies with NIH
standards.
The animals were deeply sedated with isoflurane throughout the surgical procedures and
injury. Eighty-four male C57BL/6 mice (approximately 8 weeks of age and weighing
approximately 22–24 g) were randomly divided into CCI (n = 38), craniotomy-only (n =
36), or control (n = 10) groups. CCI and craniotomy mice were further divided into 7-day (n
= 14/group), 14-day (n = 12/group), and 28 day (10–12/group) subgroups. Craniotomy-only
mice received the same surgical procedures as CCI without the cortical impact. Two control
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groups included naïve mice (n = 6) that did not receive an incision, craniotomy, or CCI
(naïve group), and incision-only mice (n = 4) that received a skin incision only without
craniotomy or CCI (incision-only group). All mice were allowed to recover from anesthesia
and kept in separate cages postoperatively with unrestricted food and water. Animals were
euthanized with a lethal dose of pentobarbital (120 mg/kg, intraperitoneal [I.P.]) for post-
mortem histological analysis.
TBI
TBI was produced using a CCI injury model, as described previously by our laboratory in
mice.29–32 Mice were anesthetized with isoflurane (5% induction; 2% maintenance).
Previous studies by our laboratory demonstrate that the well-established model of CCI is a
valid, accurate model to study PTH. Features of the CCI injury model in rodents include a
reproducible ipsilateral contusion to the somatosensory cortex with regions of diffuse axonal
injury, all of which have been well-described.33–39 To ensure aseptic techniques, heads were
shaved using electric clippers and prepped with betadine and alcohol prior to incision.
Thermistors (Physiotemp, Clifton, NJ, USA) were implanted into the temporalis muscle and
rectum to monitor and maintain respective brain and core temperatures at 37 + 0.5°C.The
head was fixed in a stereotaxic frame, and a high-speed drill was used to create a right-sided
4-mm craniotomy positioned at Bregma exposing the somatosensory cortex. Care was taken
to leave the dura intact, and the bone flap was removed. TBI was induced using an
electromagnetic stereotaxic impactor (Leica Biosystems Richmond formerly MyNeuroLab,
Richmond, IL, USA) consisting of a 3-mm diameter, rounded aluminum tip. CCI was
induced using the parameters of 1.0-mm depth, 3.0 m/second velocity, and 100-millisecond
contact time at an impact angle perpendicular to the cortical surface. The injury cavity is
located between 0 and −1.0 mm anterior-posterior (AP) to Bregma (Fig. 1).40,41 The
approximate location of the focal cavity core is −1.0 mm AP to Bregma and includes the
lateral primary motor cortex and primary sensory hind-limb and fore-limb regions but not
the primary sensory barrel field (Fig. 1b).41 Following injury, the bone flap was replaced
and sealed with permanent cyanoacrylate-based fast-acting adhesive closures, and the skin
sutured closed with 6.0 black silk sutures. The use of the adhesive allows the bone flap to be
reintegrated with the existing calvarium, prevents the generation of bleeding during closure,
and eliminates the risk of additional brain injury once mice awake from anesthesia that may
occur from leaving a piece of the bone plate out. A single dose of short-acting
buprenorphine (0.05 mg/kg; subcutaneous injection) was administered before removal from
isoflurane to facilitate acute postoperative recovery.
Periorbital von Frey Sensory Testing
von Frey mechanical sensory testing was performed for incision-only control (n = 4), naïve
control (n = 6), craniotomy-only (n = 36), and CCI (n = 38) mice. Mice were tested during
the daylight portion of their circadian cycle using a universal plastic tube restraint designed
for rodents up to 40 g (inner diameter 3.5 cm, length 10 cm). Mice enter the restraint device
uncoaxed. Restraint is performed without force, tight restraint or change in the degree of
restraint for a short time, less than 15 minutes; mice acclimate to the restrainer for 5–10
minutes to find their positioning plus no longer than 5 minutes of testing. The restrainer is
inverted at a 30-degree angle incline, as mice prefer an upward facing position that
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facilitates rapid entry into testing position and prevents mice from turning around during
testing (Fig. 2). Baseline, 7-, 14-, 21-, and 28-day post-tests were conducted on all mice. von
Frey monofilaments (North Coast Medical, Inc., Morgan Hill, CA, USA) with calibrated
bending forces according to the size of the filament were used to test for periorbital sensory
changes (periorbital allodynia). Allodynia refers to an abnormal response to a stimulus that
would be innocuous under normal conditions. von Frey sensory testing is a well-known
validated method to test for allodynia in rodents and evaluate sensory changes after central
nervous system (CNS) injury.42 von Frey sensory testing was adapted from established
protocols used by the laboratories of Oshinsky for periorbital testing18,43 and Winkelstein
for forepaw testing44–46 in rats. Specifically, von Frey forces were modified to take into
account the lower thresholds typically observed in normal control mice (<2.0 g) rather than
the higher forces typically used for testing rats (up to 10 g).47,48 Mechanical thresholds were
determined by applying the von Frey monofilaments to the periorbital region on the right
and left side of the face over the rostral portion of the eye and distal from the suture site. In
order for a stimulation to elicit a positive response, the filament must make firm
perpendicular contact with the skin, causing the filament to bend and thereby producing a
precise bending force that was previously calibrated by the manufacturer. A positive
response was characterized by the following criteria: mouse vigorously stroked its face with
the forepaw, head withdrawal from the stimulus, or head shaking. During our preliminary
studies, the von Frey stimuli were presented in a sequential ascending order to determine the
range of filament threshold forces in our mouse model (0.008–2.0 g) to be used for all
testing. From our preliminary studies, filaments with graded forces (0.008, 0.02, 0.04, 0.07,
0.16 g) were designated as the testing filaments for all baseline measures and post-testing.
For baseline and post-test measures, each mouse was stimulated 10 times bilaterally with
each filament. Force thresholds were defined as greater than a 50% response frequency for a
von Frey stimulus. Baseline threshold values and naïve data showed a mean force threshold
to fall between 0.07 and 0.16 g. Periorbital thresholds for each filament are presented as
mean threshold (g) ± standard error of the mean (SEM).
Immunohistochemistry
Immunohistochemistry was performed on 6 control (3 naïve controls and 3 incision-only
controls), 16 craniotomy-only, and 16 CCI mice to evaluate the changes in SP and the time-
course for microglial/macrophage and astrocytes activation. Immunohistochemical
techniques were utilized for these analyses in order to characterize both the temporal and
spatial changes within the brain regions of interest (ROI), primarily the somatosensory
cortex and medullary trigeminal zones. On postoperative days 7, 14, and 28, mice were
administered a lethal dose of sodium pentobarbital and underwent cardiac perfusion with
heparinized saline, followed by 4% paraformaldehyde. Brains were quickly removed and
post-fixed in 4% paraformaldehyde for 2 hours at which point they were transferred to 30%
sucrose in PO4 buffer until sinking for cryo-protection. Brains were divided into brainstem
and forebrain regions, and sectioned coronally with a cryostat at −24°C (10-μm thick, 1 : 10
series, 100 microns between series), and air-dried overnight.
Immunohistochemical analyses were performed on forebrain (Bregma +1.10 to −2.5 mm)
and/or brainstem tissues (Bregma −5.40 to −8.24 mm). Tissues were washed and incubated
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in 10% normal goat serum in O.3% Triton-100 for 1 hour. Alternate sections were labeled
using the following primary rabbit antibodies: (1) SP, a nociceptive neuropeptide (1 : 250;
Millipore catalog no. AB1566); (2) ionized calcium-binding adaptor molecule-1 (Iba-1), a
cytoplasmic peptide selectively expressed in monocytes and microglia (1 : 250; Wako Pure
Chemical Industries, Osaka, Japan); (3) glial fibrillary acidic protein (GFAP) (1 : 500;
Millipore no. AB1540) specific to astrocytes. For Iba-1-labeled slides, the nuclear
counterstain DAPI (Invitrogen Life Science, Grand Island, NY, USA) was applied for
stereological cell counting. After 24 hours of incubation with the primary antibody at room
temperature, tissues were incubated with fluorescent secondary antibodies DyLight 488- or
549-conjugated AffiniPure Goat anti-rabbit immunoglobulin G (Jackson ImmunoResearch,
West Grove, PA, USA) for 2 hours. Negative control staining was performed by omitting
the primary antibodies.
Quantification of SP, GFAP-Labeled Astrocytes, Iba-1-Labeled Macrophage/Microglia
Images were captured using an Olympus BX-51 (Center Valley, PA, USA) and Image
capture software, SPOT Advanced (Sterling Heights, MI, USA). Quantification of %SP and
GFAP immunoreactivity were performed, as described previously by Elliott and colleagues
for 20× red blue green (RBG) images using ImageJ software (version 1.43J, NIH, Bethesda,
MD, USA).23,24,26 Although SP immunoreactivity was present in some rostral brainstem
sections during our preliminary investigation, majority of the SP immunoreactivity was
present in the caudal trigeminal nucleus. Therefore, subsequent quantification of SP was
performed for the trigeminal nucleus caudalis region (−7.76 to −8.24 mm Bregma) identified
using the mouse brain atlas by Franklin and Paxinos.41 Briefly, quantification of SP
immunoreactivity included 3 square ROI (0.146 mm2) used to measure 3 sections within the
trigeminal nucleus caudalis per mouse brain. Immunohistochemistry was chosen to evaluate
changes in SP in order to determine the anatomic regions of the brainstem that were
affected.
Quantification of percent GFAP immunoreactivity on 20× RBG images using ImageJ
software included 3 square ROI (0.28 mm2) measured from the preserved tissue adjacent to
the injury cavity for 3 sections per brain between −0.5 and −1.0 mm posterior to Bregma (9
measurements per mouse). The color threshold for the RBG image was set to select the
green fluorescent GFAP immunoreactive product, and the pixel count was measured and
recorded. Using the color-thresholding feature available from ImageJ, the pixel threshold is
set so that fine processes of quiescent astrocytes were measured. The total number of pixels
was then measured by selecting all the pixels in the region of interest to ensure consistent
sampling between specimens and recorded. Subsequently, percent GFAP immunoreactivity
is calculated as the measured thresholded immunofluorescent product in pixels divided by
the total pixels the region of interest. The percent immunoreactivity for the 6 ROI was
averaged and reported as mean ± SEM.
Unbiased stereological analyses for cell counting was performed using similar methodology
as previously described by our laboratory.49 Using the Spot Advanced image capture
software and NIH ImageJ 1.43, Iba-1 cells are counted in 5 non-overlapping, high-power,
rectangular counting frames (high-power field [HPF], 300 μm × 220 μm) at 400×
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magnification selected from preserved perilesional tissue for 3 sections per brain. HPFs in
naïve animals were selected from tissue sections corresponding to the location of the lesion
in injured animals. Within each field, only those positively staining cells with a nucleus in
the focal plane were counted.
Cell-specific components of the neuroinflammatory response to injury were evaluated for
Iba-1-labeled macrophages/microglia and GFAP-labeled astrocytes utilizing estimated cell
counts and percent immunoreactivity, respectively. Different methodology was used for the
assessment of glial responses because these individual glial cell populations undergo
different morphologic changes after injury. In particular, reactive astrocytes hypertrophy and
elongate their processes, whereas microglia retract their processes. Although both increase
the production of the proteins of interest, the hypertrophic and elongated processes
characteristic of a reactive astrocyte phenotype are more suited for quantifying the percent
immunoreactivity and allows for a more rapid means to quantify changes; cell counts were
utilized to evaluate the macrophage/microglial component of the cellular neuroinflammatory
response because infiltrating macrophages in addition to migrating and proliferating
microglia are known to contribute to the increase in the number of Iba-1-labeled cells.
Circulating macrophages and resident activated microglia are not distinguishable by our
immunohistochemical techniques.
Enzyme-Linked Immunosorbent Assay for CGRP
After mice (6 control, 17 craniotomy, and 20 CCI) were euthanized with a lethal dose of
sodium pentobarbital (120 mg/kg, I.P.), brains were rapidly dissected, and brainstem tissues
were flash frozen in liquid nitrogen and stored at 80°C. Brainstem tissues were sectioned
according to the mouse brain atlas by Franklin and Paxinos (−5.40 to −8.24 mm Bregma) to
include the beginning of the spinal trigeminal tract to the most caudal section of the spinal
trigeminal nucleus (ie, trigeminal nucleus caudalis).41 Thus, any detection of CGRP will
most likely be released from the central terminals of the trigeminal ganglion at the
medullary trigeminal nuclei, although additional sources of CGRP from other sensory
afferents were not excluded from our samples.50 All brainstem samples were homogenized
unpooled with ethylene-diamine tetraacetic acid-free complete protease inhibitor cocktail
tablets using 50 μL/10 mg of tissue (Roche Diagnostics, GMPH, Basel Switzerland).
Homogenates were centrifuged at 14,000 rpm for 15 minutes at 4°C. Total protein content
for each sample was determined using BCA-200 protein assays (Bicin Choninic Acid,
Pierce, Rockford, IL, USA). Tissue lysates were analyzed for CGRP according to the
manufacturer’s protocol (CGRP enzyme-linked immunosorbent assay [ELISA] Kit; Cayman
Chemicals, Ann Arbor, MI, USA; cat# 589001). Each sample was run in duplicate, and data
(pg CGRP protein) were normalized to mg total protein.
Statistical Analyses
To determine the effects of CCI and craniotomy on ipsilateral and contralateral periorbital
mechanical sensory responses, 2-way analysis of variances (ANOVAs) were used with the
factors: time (baseline, 7, 14, 21, and 28) and group (naïve, incision-only, craniotomy-only,
and CCI). ANOVAs were followed by Bonferroni post-hoc tests for multiple comparisons
with adjusted P values. Single-factor bonferroni post-hoc analyses were also performed to
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evaluate within group comparisons to compare each week to baseline data and at matching
temporal endpoints for between group comparisons. To analyze group differences for SP,
Iba-1, and GFAP immunohistochemical and CGRP ELISA data, group comparisons were
made using single univariate ANOVA, followed by Bonferroni post-hoc comparisons with
an adjusted P value. The following group comparisons were performed: (1) 7-, 14-, and 28-
day craniotomy-only compared with control; (2) 7-, 14-, and 28-day CCI mice compared
with control; (3) craniotomy-only compared with CCI groups at matched 7-, 14- and 28-day
endpoints. A Pearson’s correlation analysis was used to examine the relationships of CGRP
and SP with periorbital allodynia. All data were analyzed using the GraphPad Prism 5
statistical program (La Jolla, CA, USA). Significance levels were set at P < .05 for all
statistical analyses, adjusted P values are reported, and data are reported as the mean and
SEM.
RESULTS
Periorbital von Frey Thresholds
Daily von Frey testing was performed to measure baseline thresholds and determine whether
there was any effect of repeated temporary (>15 minutes) restraint over time in 4 naïve
mice. Mean baseline threshold was 0.11 ± 03 g in naïve mice over time. Baseline, right vs
left von Frey thresholds were not significantly different, P = .22. Repeated, daily restraint
did not alter right and left baseline von Frey thresholds, P = .31 and .53, respectively. von
Frey sensory testing for incision-only mice showed no changes from baseline periorbital
mechanical thresholds for up to 14 days after incision, P = .97 (Fig. 3A). Mean ipsilateral
peri-orbital thresholds showed significant differences by group (P < .0001 and F = 30.19)
and time (P < .0001 and F = 9.031), and a significant interaction (P < .04 and F = 2.649).
CCI resulted in reductions in mean periorbital thresholds (mean threshold range 0.01–0.03
g) that were consistently lower (nearly 10-fold) compared with craniotomy-only mean
thresholds (0.05–0.09 g). Post-hoc analyses showed that mean ipsilateral periorbital
threshold was significantly reduced (periorbital allodynia) in CCI mice compared with
baseline at 7 days (P < .001), 14 days (P < .001), 21 days (P < .001), and 28 days (P < .001)
after injury (Fig. 3B). Mean ipsilateral periorbital thresholds were significantly reduced in
CCI mice compared with craniotomy-only mice at 7 days (P < .001), 14 days (P < .01), 21
days (P < .001), and 28 days (P < .001) after injury. Mean ipsilateral threshold was
significantly reduced in the craniotomy-only group compared with baseline at 14 days (P < .
001). Mean ipsilateral thresholds for 7-, 21-, and 28-day craniotomy mice were not
statistically different from baseline threshold. ANOVA results for mean contralateral
thresholds showed significant differences by group (P < .003 and F = 9.049) and time (P < .
002 and F = 4.584) and no significant interaction (P = .57 and F = 0.7262). Post-hoc
analyses reveal that mean contralateral threshold was significantly reduced in CCI groups
compared with baseline at 7 (P < .01), 14 (P < .001), 21 (P < .001), and 28 days (P < .01)
(Fig. 3C). Mean contralateral threshold was significantly reduced in CCI groups compared
with craniotomy at 21 and 28 days after injury (P < .05). Mean contralateral threshold in
craniotomy-only mice was significantly reduced compared with baseline at 14 days (P < .
001). Mean contralateral thresholds in craniotomy mice at 7, 21, and 28 days were not
statistically different from baseline threshold. There were no significant group differences
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for contralateral thresholds between CCI and craniotomy at 7 and 14 days after injury in
which were contralateral thresholds generally higher (less sensitive) than ipsilateral
thresholds.
Neuropeptides
There were no differences found for any of the cellular responses or neuropeptides of
interest between naïve and incision-only control mice. Therefore, the naïve control and
incision-only control groups were combined and presented as a control group (control) for
all post-mortem immunohistochemical and ELISA analyses.
Immunohistochemical examination of brainstem tissues showed SP immunoreactivity
throughout the length of the trigeminal tract and nuclei (rostral to caudal, −5.4 to −8.0 mm
posterior to bregma), with the greatest immunoreactive product appearing bilaterally in the
most caudal part of the brainstem, the trigeminal nucleus caudalis. There was no difference
in naïve and incision-only controls that show a low level of SP immunoreactivity, and
therefore, groups were combined under 1 control group for analysis (Fig. 4). High-power
micrographs show SP immunoreactive product appearing in a punctuate pattern in the
trigeminal nucleus caudalis (Fig. 4D,E). SP immunoreactivity in the trigeminal nucleus
caudalis was significantly increased in CCI mice at 7 and 14 days, and in craniotomy-only
mice at 7 days compared with control mice (ANOVA P = .0001, and F = 19.16 and 25.62).
Post-hoc comparisons show that SP immunoreactivity was significantly increased in CCI
mice at 7 (P < .001 and P < .01) and 14 days (P < .05) compared with control and
craniotomy mice. SP immunoreactivity was also transiently increased in craniotomy mice on
postoperative day 7 compared with controls, P < .001. SP immunoreactivity in CCI mice at
28 days after injury was not statistically different compared with control mice. There were
also no significant increases in SP immunoreactivity in craniotomy-only mice at 14 and 28
days compared with control mice. Pearson’s correlation showed that there was no significant
correlation between SP and periorbital von Frey thresholds, r = −0.20.
CGRP levels for naïve and incision-only mice were not significantly different and were
reported as controls (Fig. 5). CCI mice had a significant increase in CGRP levels in
brainstem tissues compared with control and craniotomy mice (ANOVA P < .0001, and F =
14.39 and 14.38). CGRP levels were significantly increased in CCI mice at 7 (P < .01), 14
(P < .05), and 28 days (P < .01) after injury compared with control mice (Fig. 5). CGRP
levels were significantly increased in CCI mice compared with craniotomy-only mice at 7 (P
< .05) and 28 days (P < .001) after injury (F = 19.58). CGRP levels were significantly
increased in craniotomy-only mice at postoperative days 7 and 14 (P < .05 and P < .001,
respectively) but not statistically different at 28 days compared with control mice. Increased
CGRP levels was significantly correlated with decreased periorbital mechanical thresholds,
P < .0001 and Pearson’s r = −0.65.
Macrophage/Microglia and Astrocyte Responses
The number of Iba-1-labeled macrophage/ microglia in the somatosensory cortex for naïve
and incision-only mice was not statistically different, in which group cell counts were
combined and reported as controls (Fig. 6). There were significant increases in the number
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of perilesional Iba-1 immunoreactive macrophage/microglia at 7, 14, and 28 days after CCI
compared with control mice (ANOVA P < .0001 and F = 27.17). The greatest number of
Iba-1 cells was found at 7 days after CCI, in which there was a progressive decline in
numbers at days 14 and 28 (Figs. 6 and 8). Post-hoc results show that the number of
perilesional Iba-1 cells was significantly increased in CCI mice at 7 (P < .001), 14 (P > .
001), and 28 days (P < .05) compared with control mice. Also, the number of perilesional
Iba-1 cells was significantly increased in CCI compared with craniotomy-only at 7 and 14
days after injury, P < .001 and P < .01, respectively (Fig. 6). There was no significant
increase in the number of Iba-1 cells in the contralateral cortex or in craniotomy-only mice
at any time point. Although the number of macrophage/microglia were not significantly
increased in craniotomy-only mice at any time point examined, increased Iba-1 macrophage/
microglial immunoreactivity was noted in the area that delineates the craniotomy site
depicted in Figure 6, which was completely resolved by 28 days after craniotomy. It should
be noted that a methodological limitation of this study is that our cell count technique does
not include analysis of the morphological changes that microglia undergo during various
stages of activation.
Astrocyte GFAP immunoreactivity in the somatosensory cortex for naïve and incision-only
mice was not statistically different and percent GFAP immunoreactivity values were
combined and reported as controls (Fig. 7). ANOVA revealed that GFAP immunoreactivity
in the somatosensory cortex was significantly increased in 7-day CCI mice, and 7- and 14-
day craniotomy-only mice (ANOVA P < .0001; F = 19.37 and 26.15 for CCI and
craniotomy, respectively) compared with controls. Post-hoc comparisons showed increased
GFAP immunoreactivity in the ipsilateral cortex in CCI mice at 7 days compared with
controls (P < .001). There was no significant increase in GFAP immunoreactivity in the
somatosensory cortex in CCI mice at 14 and 28 days post-injury compared with controls
(Figs. 7 and 8). GFAP immunoreactivity in craniotomy-only was significantly increased on
postoperative days 7 and 14 but not 28 days compared with control mice (P < .001 and P < .
05, respectively). There was no significant increase in GFAP immunoreactivity in the
contralateral cortex compared with controls at any time point (data not shown).
DISCUSSION
Cortical Injury Induces Glial Activation in the Somatosensory Cortex, Increased Central
Neuropeptides, and Sensory Changes That Are Distinct From Craniotomy-Only
Important findings from the present study are the significant group differences between CCI
and craniotomy-only groups for all outcome measures. In many preclinical studies of TBI,
craniotomized animals have been used as sham controls; however, recent studies show tissue
trauma in the brain and behavioral abnormalities after craniotomy.18,20,51 It is important to
note the finding of mild, transient allodynia, changes in neuropeptides and gliosis in our
craniotomy-only group. The presence of mild periorbital allodynia in the brainstem in
craniotomized mice is not surprising given the common finding of chronic headache in
patients (50% of patients) undergoing craniotomy for pathology other than direct head
trauma (eg, elective aneurysm clipping and tumor resection).52 A study by Oshinksy et al
also reported that rats receiving saline through a cannula had a small reduction in periorbital
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thresholds at 2 weeks post-craniotomy. A key difference between our study and the study by
Oshinsky et al is rats with thresholds that did not return to baseline at 7 days post-
craniotomy were excluded as controls from the Oshinsky study. Conversely, reports of
increased cytokines in the cerebral cortex and meninges of craniotomized control rats
accompanied by deficits on neurological and acoustic startle tests demonstrate that
craniotomy induces a form of mild tissue trauma in the brain.20,51 Proposed mechanisms for
post-craniotomy headache include trauma to the pericranial muscles and periosteum, dural
irritation, reduced volume of cerebrospinal fluid, and aseptic meningitis.53 Even slight glial
activation may produce mediators such as pro-inflammatory cytokines, inducible NO, or
excessive glutamate that can transiently stimulate dural nociceptors. In addition, Stokely et
al reported a significant increase in activated dural mast cells after craniotomy that was
accompanied by increases in histamine and blood-brain-barrier permeability changes in the
cerebral cortex.54 Histamine release by activated mast cells may be an additional source of
transient sensory changes induced by craniotomy in our model.
Periorbital Mechanical Allodynia Persists After Cortical Impact
Mean baseline periorbital von Frey mechanical threshold was 0.11 ± 0.5 g (individual
thresholds ranged between 0.07 and 0.6 g) in a mouse model of CCI. Baseline von Frey
thresholds were within the reported threshold range (0.04–2.0 g) for paw or trunk von Frey
testing in murine models of neuropathic pain.47,48,55 Overall, CCI resulted in reductions in
mean periorbital thresholds (mean threshold range 0.01–0.03 g) that were consistently lower
compared with baseline (0.07–0.6 g) and craniotomy-only thresholds (0.05–0.09 g). Similar
sensory changes were demonstrated in a mouse model of spinal contusion in which an
increased response frequency was reported for a 0.02-g von Frey stimulus applied to the
trunk.47 Reductions in von Frey thresholds in our mouse CCI model are also comparable
with the reductions noted in rat neuropathic pain models; however, thresholds for rats are
typically on a higher scale compared with mice. In rats, periorbital or forepaw baseline
thresholds ranged between 8 and 10 g or higher, and were reduced to <2 g in models of
migraine or cervical nerve compression.18,25,46,56
A significant reduction in periorbital thresholds in response to von Frey mechanical stimuli
(periorbital allodynia) was sustained up to 4 weeks after CCI injury. Our finding of
allodynia after CCI is consistent with studies in headache models, in which chemical
stimulation of the dura resulted in periorbital allodynia lasting weeks after the final
infusion.18,57 Although periorbital and facial allodynia have been shown in migraine models
and human migraine patients, this is the first study to report persistent periorbital allodynia
in a model of TBI.18–20 An intriguing finding is that periorbital allodynia persisted over 4
weeks, while macrophage/microglia and astrocyte responses were declined. Because
microglial and astrocyte responses are near resolution by 4 weeks, the finding that sensory
changes are sustained leads to the hypothesis that additional mechanisms maintain the
observed behavior. Pro-inflammatory mediators and/or excitatory neurotransmitters released
transiently in the traumatized brain may repeatedly stimulate meningeal sensory afferents,
activate the trigeminal nociceptive pathway, and in turn induce central sensitization and
elicit abnormal sensory responses.
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Sensory changes have been reported in studies using a midline fluid percussion model of
TBI.17,58 Persistent sensitivity to whisker stimulation after fluid percussion injury was
associated with synaptic plasticity within the cortical barrel field.58 Peripheral sensory
afferents of the trigeminal ganglia that supply the periorbital cutaneous skin also innervate
the rodent facial whisker pad, as well as the meninges and cerebral vasculature. A
combination of inflammation, hyperexcitation, and disrupted circuitry in the thalamus and
cortex were proposed mechanisms for increased neuronal activation in the thalamus and
whisker hypersensitivity after midline fluid percussion injury.17,58,59 Although there is no
gross morphologic damage or glial activation within the cortical barrel field in our injury
model, changes in synaptic function, molecular inflammatory mediators, and neuronal
activation in this area along with other sensory cortices cannot be ruled out and may explain,
in part, sensory changes observed in our study. In sum, we propose that allodynia in our
model may be due to either repeated activation of meningeal nociceptors and central
sensitization, as well as possibly enhanced activation of cortical sensory neurons.
There are a number of excellent reviews describing the potential mechanisms of migraine,
such as nociceptor and central sensitization, which may contribute to the periorbital
allodynia observed in our model of TBI.60–63 Central sensitization may result from repeated
nociceptor sensitization or independent mechanisms. Central sensitization refers to a
heightened sensitivity (ie, lowered activation threshold and increased responsiveness to
synaptic input) of higher order neurons.13,57 Upon central sensitization of the
trigeminovascular system, the function of neurons in the medullary brainstem, upper
cervical spinal cord dorsal horn, or in the thalamus and cortex may be altered. According to
Woolf and Salter, long-lasting alterations in the expression of transmitters, receptors, or ion
channels may alter the normal response characteristics to innocuous stimuli, in turn eliciting
allodynia.13 Other post-traumatic disturbances such as sensitization of cortical sensory
neurons, loss of inhibitory interneurons or synapses, and cortical spreading depression are
potential contributors to a prolonged reduction in periorbital threshold in our CCI model.
The precise mechanism of allodynia in our model remains elusive, although nociceptor
sensitization is evidenced by increases in CGRP and SP. A limitation of our study is that the
nociceptive neuropeptide changes in the dura and trigeminal ganglia after TBI were not
determined. In addition, the effects of injury on other central components of the
trigeminovascular pain circuitry, such as thalamic and cortical neurons, warrant further
examination.
On a final note with regards to allodynia, the presence of bilateral allodynia in the absence
of bilateral glial responses in the uninjured somatosensory cortex in our CCI model requires
further investigation that is beyond the scope of our study. It is plausible that bilateral
allodynia elicited in our model may be due to bilateral changes in pro-inflammatory or
excitatory sensitizers known to stimulate nociceptors or possibly alter the excitability of
cortical sensory neurons or another unidentified mechanism.
Increases in Central Neuropeptide Levels Persist After Cortical Impact
Our data show increased SP immunoreactivity within the trigeminal nucleus caudalis to
persist for 14 days after CCI compared with craniotomy-only; however, SP
Elliott et al. Page 12













immunoreactivity was back to naïve levels by 28 days post-injury. A previous study by our
laboratory showed elevated SP immunoreactivity within the trigeminal nucleus caudalis 2
days after CCI.29 Although our previous findings indicate that SP is involved in the acute
responses to TBI, present findings for changes in SP in the brainstem did not persist nor did
they correlate with periorbital allodynia, as was found for CGRP. Combined, our past and
present findings suggest that SP may be a therapeutic target for the acute neurogenic
inflammatory-related effects of TBI; however, findings point to other targets for prolonged
sensory changes.
Increases in CGRP levels in the brainstem persist for 4 weeks after CCI. Increases in CGRP
were significantly correlated with periorbital allodynia in our CCI model. Examination of
CGRP in the brainstem was based on evidence that the trigeminal ganglion is known to be
the primary source of CGRP, whereby CGRP is released in the brainstem from the central
terminals of the ganglion.64,65 CGRP immunoreactivity limited to sensory fibers has been
reported in the superficial laminae of the spinal trigeminal nuclei and extending into the
spinal trigeminal tract in rats.66 In a study of diffuse TBI, CGRP in serum was increased for
up to 7 days after injury.67 Increases in nociceptive neuropeptides, CGRP, and SP found by
our laboratory and others are in contrast with the acute reductions in CGRP reported by
Armstead and colleagues in which these differences may be explained by the time point
examined.29,68–70 A series of studies by Armstead and colleagues show that decreases in
CGRP in the injured brain during the acute injury phase, within hours after TBI, contributes
to impaired cerebral pressure autoregulation.69,70 To the best of our knowledge, our study is
the first to report CGRP changes in the brainstem over weeks after injury in a model of TBI.
Sensory afferents of the trigeminal ganglion relay nociceptive information to the brainstem
trigeminal complex by releasing CGRP and SP.18,58,71,72 A proposed mechanism driving the
initial increases in SP and CGRP after CCI and craniotomy may be the early glial-derived
neuroinflammatory cascades acting to stimulate and sensitize nociceptors within the
meninges. Inflammatory mediators facilitate nociceptor neurotransmission through directly
stimulating trigeminal nociceptors via the transient receptor potential cation channel
subfamily V member 1 (TRPV1) receptor or lowering the threshold of trigeminal
afferents.63 For example, cytokines, prostanoids, bradykinin, and protons and products of
mast-cell degranulation (eg, serotonin, prostaglandin I2, and histamine) released during
inflammation are potential sources of nociceptor sensitization after TBI. If the activation
threshold of sensory neurons is lowered due to sensitization, subsequent mechanical
stimulation of sensory afferents of the trigeminal ganglia using von Frey filaments may
trigger increases in nociceptive neuropeptides.73 In sum, we propose that increases in SP
and CGRP suggest injury to cortex induces sensitization of nociceptors.
Glial Activation Progressively Declines Over Time After Cortical Impact
In the present study, we found that a significant increase in the number of macrophage/
microglia in the injured somatosensory cortex was greatest at 7 days followed by
progressive declines at 14 and 28 days, although numbers remained significantly increased
above control levels. In our previous study, acute increases in the number of macrophage/
microglial activation at 2 days after CCI were at even higher numbers (31% more) compared
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with our present results at 7 days.29 This decline in the number of Iba-1-labeled cells over
time is mostly likely due to a reduction in the number of infiltrating macrophages; however,
the different cell types were not distinguishable in the present study. In contrast with
macrophage/microglia responses, a significant increase in astrocyte GFAP immunoreactivity
was found only at 7 days after CCI. Studies by other laboratories using the CCI injury model
report localized microglial and astrocyte activation in the injured cortex and hippocampus to
peak around 3 days, persist up to 14 days, with subsequent resolution by 28 days post-
injury.34,74,75 Findings that the macrophage/microglial response precedes and outlasts the
astrocyte response to TBI has been previously reported.75 Results that macrophage/
microglial activation lasts longer compared with astrocyte reactivity suggest that these glial
populations make unique contributions to the proposed meningeal nociceptor sensitization
or activation of cortical sensory neurons. We propose that transient macrophage/ microglia
and astrocyte activation in the somatosensory cortex over weeks after injury may contribute
to the early events involved in sensitization of dural nociceptors, as evidenced by increases
in nociceptive neuropeptides. More importantly, glial activation in the cortex did not
correlate with CGRP or periorbital allodynia because both were sustained when gliosis in
the cortex declined over time.
Glial activation in the CNS contributes to the initiation and maintenance of chronic pain
states.76,77 Activation of microglia has been implicated in the pathophysiologic mechanisms
of both migraine and chronic pain.76,78 Macrophage/microglia are considered to be the
predominant source of pro-inflammatory cytokines and inducible nitric oxide synthase
(iNOS) after TBI, although astrocytes and neurons are also cellular sources.79 Pro-
inflammatory cytokines directly sensitize nociceptors and promote pro-nociceptive
pathways such as cyclooxygenase-2-mediated prostanoid release.80,81 NO and constituitive
isoforms of NOS, endothelial and neuronal NOS, contribute to the pathology of migraine
and TBI; however, the role of iNOS is unclear.82,83 In mice, infusion of an NO donor
induced hindpaw allodynia along with increased neuronal activation in the trigeminal
nucleus caudalis and upper cervical spinal cord.84
In addition, astrocytes have important functions in the neurovascular unit, as well as
glutamate uptake in which reactive astrocytes, as found in our injured brain, may contribute
to altered neuronal function. Reactive and/or swollen astrocytes after TBI may have a
reduced capacity to clear glutamate, in turn contributing to hyperexcitatory conditions.85
Although cortical glial-derived mediators would be expected to promote increases in
excitability, it remains to be determined whether there are significant changes in the
excitability of sensory cortical neurons that contribute to allodynia in our injury model.
Whether altered microglia and astrocyte function occurs in other regions of the trigeminal
sensory pathway aside from the somatosensory cortex remains to be determined. In sum, our
findings that glial activation is outlived by increases in CGRP, as well as allodynia indicate
additional mechanisms maintain these changes. Additional, more extensive analysis of
candidate molecular mediators, particularly in the dura, trigeminal ganglia, and caudal
brainstem regions, is warranted.
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CONCLUSIONS AND FUTURE DIRECTIONS
Injury to the somatosensory cortex induces increases in CGRP levels in the brainstem and
bilateral periorbital allodynia persisting up to 4 weeks after injury. SP immunoreactivity was
also transiently increased after cortical injury. Combined, changes in central neuropeptides
and sensory behavior in a mixed focal and diffuse cortical injury model of TBI are indicative
of abnormally sustained activation of the trigeminovascular system. The increases in CGRP
and allodynia outlast the increases in macrophage/ microglial and astrocytes activation.
These findings provide evidence for the chronification of TBI-induced sensory alterations in
which local glial activation in the somatosensory cortex may not be required for
maintenance of these changes. This work provides a foundation upon which to build future
TBI studies investigating mechanisms of PTH. The current range of TBI models including
CCI allow for studies of preserved neuronal circuits of interest, such as those along the
trigeminovascular pain pathway that may contribute to PTH. Adaptations to the CCI model
to a milder, diffuse TBI without a focal injury or closed head injury may be used for
comparative studies to understand the differences in PTH pathology between different types
of injuries.
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Images depict a sagittal (A) and coronal (B) view of a mouse cortical impact injury. Image
A shows the location of the impactor tip over the sensory cortex on a sagittal mouse brain
section adapted from the Allen Mouse Brain Atlas (http://mouse.brain-map.org).40 Image B
shows a nissl stained brain section at approximately −1.0 posterior to Bregma showing the
location of the cavitation core in the somatosensory cortex after impact injury. The
somatosensory cortex regions according to The Mouse Brain Atlas by Franklin and
Paxinos41 are indicated by numbers 1–4 including primary motor cortex (1), primary
sensory cortex hind-limb region (2), primary sensory cortex forelimb region (3), and
primary sensory cortex barrel field (4).41 Gross morphologic damage after cortical impact
injury induced by our laboratory includes primary motor and sensory hind limb and fore
limb but not the barrel field.
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Image of von Frey monofilament and restrainer apparatus used for evaluating periorbital
mechanical sensory changes (allodynia). Inset indicates regions where periorbital von Frey
stimulus is applied (white x) during testing. C57BL6 black eyes are delineated by white dots
to indicate the location relative to stimuli.
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Mean periorbital threshold (g) in response to von Frey (mechanical) stimuli for an incision-
only, controlled cortical impact (CCI) and craniotomy-only groups, n = 8–12/group. Mean
periorbital threshold for incision-only mice showed no changes from baseline periorbital
mechanical thresholds over 2 weeks (A). Mean ipsilateral periorbital threshold was
significantly reduced in CCI mice compared with baseline at 7 (***P < .001), 14 (***P < .
001), 21 (***P < .001), and 28 days (***P < .001) after injury (B). Mean ipsilateral
periorbital thresholds was significantly reduced in CCI mice at 7 (###P < .001), 14 (##P < .
01), 21 (###P < .001), and 28 days (###P < .001) after injury compared with craniotomy-only
mice. Mean ipsilateral threshold was significantly reduced in the craniotomy-only mice at 14
days compared with baseline (***P < .001). Mean ipsilateral thresholds for 7-, 21-, and 28-
day craniotomy mice were not statistically different from baseline threshold. (C) Mean
contralateral threshold was significantly reduced in CCI groups compared with baseline at
7(**P < .01), 14 (***P < .001), 21 (***P < .001), and 28 days (**P < .01). Mean
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contralateral threshold was significantly reduced in CCI groups at 21 and 28 days after
injury compared with craniotomy (#P < .05). Mean contralateral threshold in craniotomy-
only mice at 14 days was significantly reduced compared with baseline (***P < .001). Mean
thresholds in craniotomy mice at 7, 21, and 28 days were not statistically different from
baseline threshold. There were no significant group differences for contralateral thresholds
between CCI and craniotomy at 7 and 14 days after injury.
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Percent substance P (SP) immunoreactivity in the spinal trigeminal nucleus in controlled
cortical impact (CCI) and craniotomy mice at 7, 14, and 28 days after injury, n = 6/group.
SP immunoreactivity was increased in CCI mice compared with control mice at 7 (***P < .
001) and 14 days (*P < .05). SP immunoreactivity was increased in CCI mice compared
with craniotomy mice at 7 (##P < .01) and 14 days (#P < .05). SP immunoreactivity was
increased in 7-day craniotomy-only mice compared with control (***P < .001). SP
immunoreactivity in 28-day CCI, 14-day craniotomy-only, and 28-day craniotomy-only
mice were not significantly different compared with control mice. SP immunofluorescent
images of incision control (A and D), craniotomy-only (B), and CCI mice (C and E). Note:
SP immunoreactivity is not visible in control brains under low 4× magnification (A) though
a low level of staining is visible under higher 60× magnification (D). Increases in SP
immunoreactivity is visible in craniotomy-only mice (arrowheads, B) and CCI mice
(arrowheads, C). Note the absence of SP immunostaining in the middle region of the caudal
trigeminal nucleus in craniotomy mice (B), whereas increased SP is shown throughout the
entire dorsal-to-ventral regions of the caudal trigeminal nucleus in CCI mice (C). High-
power micrographs showing SP immunoreactive product appearing in a punctuate pattern in
incision control (D) and increased in CCI (E) caudal trigeminal nucleus. White scale bars =
100 μm. Color images are available online.
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Calcitonin gene-related peptide (CGRP) levels (pg/mg of protein) in the brainstem measured
using enzyme-linked immunosorbent assay. CGRP levels were significantly increased in
controlled cortical impact (CCI) mice compared with control mice at 7 (**P < .01), 14 (*P
< .05), and 28 days (**P < .01) after injury (A). CGRP levels were significantly increased in
CCI mice compared with craniotomy-only mice at 7 (#P < .05) and 28 days (###P < .001)
after injury. CGRP levels were significantly increased in 7- and 14-day craniotomy-only
compared with control mice (*P < .05 and ***P < .001, respectively). CGRP levels were
not significantly different between 28-day craniotomy-only and control mice. Increases in
CGRP levels were significantly correlated with decreases in periorbital von Frey thresholds,
P < .0001 and Pearson’s r = −0.65 (B).
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Ionized calcium-binding adaptor molecule-1 (Iba-1+) microglial/macrophage cell counts in
the right somatosensory cortex of controlled cortical impact (CCI) and craniotomy groups at
7, 14, and 28 days after injury and control mice, n = 6/group. The number of perilesional
microglia/macrophage cells was significantly increased in CCI compared with control mice
at 7 (***P < .001), 14 (***P < .001), and 28 days (**P < .01) after injury. The number of
perilesional microglia/ macrophage cells was significantly increased in CCI compared with
craniotomy mice at 7 (###P < .001) and 14 days (##P < .01). Low-power images showing
Iba-1 immunoreactivity in the somatosensory cortex region of interest captured with a 4×
objective (A–D). Although the number of macrophage/ microglia was not significantly
increased in craniotomy-only mice compared with controls at any time point examined, a
slight increase in Iba-1 immunoreactivity is shown at 7 days in craniotomy-only mice under
the craniotomy site (arrowheads) (A), which was completely resolved by 28-day post-
craniotomy (B). Iba-1-labeled macrophage/microglial activation at 7 days (A, C) compared
with 28 days (B, D) in both CCI and craniotomy groups, which was not completely resolved
in the CCI group at 28 days (arrow). White scale bar = 100 μm. Color images are available
online.
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The percentage of astrocytes-specific anti-glial fibrillary acidic protein (GFAP)
immunoreactivity in the right somatosensory cortex of controlled cortical impact (CCI) and
craniotomy groups at 7, 14, and 28 days after injury and in controls, n = 6/group. GFAP
immunoreactivity was increased CCI mice compared with controls at 7 days (***P < .001)
and compared with craniotomy-only at 7 days (###P < .001). GFAP immunoreactivity was
increased in craniotomy-only mice compared with controls at 7 and 14 days after surgery,
***P < .001 and *P < .05, respectively. Images taken at 10× show GFAP-immunoreactive
astrocytes in the somatosensory cortex region of interest (A–D). Immunofluorescent images
show activated astrocytes at 7 days (A, C) compared with 28 days (B, D) in both CCI and
craniotomy groups, which was completely resolved at 28 days after craniotomy. Increased
GFAP immunoreactivity in craniotomy-only mice is shown at 7 days in craniotomy-only
mice under the craniotomy site (A). Astrocytic glial scarring (arrow) and necrotic tissue
(arrowhead) is shown at 28 days after CCI (D). White scale bar = 100 μm. Color images are
available online.
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High-power micrographs (40×) showing immunohistochemical labeling of ionized calcium-
binding adaptor molecule-1 (Iba-1) and glial fibrillary acidic protein (GFAP) with DAPI
nuclear double labeling from the somatosensory cortex of control (top A–D) and controlled
cortical impact (CCI)-injured (lower E–H) mice at postoperative day 7. Resting microglia
with thin, branched processes labeled with antibodies against Iba-1 (A), DAPI nuclear stain
(B), merged double labeling with anti-Iba-1, and DAPI (C) in an uninjured mouse brain.
Resting astrocytes double-labeled with anti-GFAP and DAPI in an uninjured mouse brain
(D). Anti-Iba-1 and anti-GFAP immunoreactivity, and the number of immunoreactive cells
are increased in the perilesional zone after CCI (E–H). Activated macrophage/microglia
cells showing retracted processes with amoeboid-like soma, increased anti-Iba-1
immunoreactivity, and cell proliferation (E), DAPI staining (F), and merged double labeling
with anti-Iba-1 and DAPI (G). Activated astrocytes showing increased GFAP
immunoreactivity with elongated, hypertrophied processes, and proliferation double-labeled
with DAPI (H). White scale bar = 25 μm.
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